Research paper
Increases in synthetic cannabinoids-related harms: Results from a longitudinal web-based content analysis

https://doi.org/10.1016/j.drugpo.2017.05.007Get rights and content

Abstract

Background

Synthetic Cannabinoid Receptor Agonists (SCRA), also known as “K2” or “Spice,” have drawn considerable attention due to their potential of abuse and harmful consequences. More research is needed to understand user experiences of SCRA-related effects. We use semi-automated information processing techniques through eDrugTrends platform to examine SCRA-related effects and their variations through a longitudinal content analysis of web-forum data.

Method

English language posts from three drug-focused web-forums were extracted and analyzed between January 1st 2008 and September 30th 2015. Search terms are based on the Drug Use Ontology (DAO) created for this study (189 SCRA-related and 501 effect-related terms). EDrugTrends NLP-based text processing tools were used to extract posts mentioning SCRA and their effects. Generalized linear regression was used to fit restricted cubic spline functions of time to test whether the proportion of drug-related posts that mention SCRA (and no other drug) and the proportion of these “SCRA-only” posts that mention SCRA effects have changed over time, with an adjustment for multiple testing.

Results

19,052 SCRA-related posts (Bluelight (n = 2782), Forum A (n = 3882), and Forum B (n = 12,388)) posted by 2543 international users were extracted. The most frequently mentioned effects were “getting high” (44.0%), “hallucinations” (10.8%), and “anxiety” (10.2%). The frequency of SCRA-only posts declined steadily over the study period. The proportions of SCRA-only posts mentioning positive effects (e.g., “High” and “Euphoria”) steadily decreased, while the proportions of SCRA-only posts mentioning negative effects (e.g., “Anxiety,” ‘Nausea,” “Overdose”) increased over the same period.

Conclusion

This study’s findings indicate that the proportion of negative effects mentioned in web forum posts and linked to SCRA has increased over time, suggesting that recent generations of SCRA generate more harms. This is also one of the first studies to conduct automated content analysis of web forum data related to illicit drug use.

Introduction

Synthetic cannabinoids are a large family of chemical substances designed to reproduce specific therapeutic/psychotropic properties of cannabis. Among these compounds, the Synthetic Cannabinoid Receptor Agonists (SCRA) mimicking Δ-9-tetrahydrocannabinol (THC) have attracted substantial attention due to their potential for abuse, their numerous emergency department presentations and increasing number of overdose-related cases reported in the US and in Europe (AAPCC, 2016, Bush and Woodwell, 2014; Cohen, Morrison, Greenberg, & Saidinejad, 2012; European Monitoring Centre for Drugs and Drug Addiction, 2013, Forrester, 2012, Riederer, 2016; Trecki, Gerona, & Schwartz, 2015). These substances belong to the Novel Psychoactive Substances (NPS) category, a heterogeneous group of substances temporarily not regulated by international legislation (Papaseit, Farré, Schifano, & Torrens, 2014; Zawilska, 2011, Zawilska and Andrzejczak, 2015). SCRA products have been available for purchase in “head shops” and through online websites since 2004 (Schifano et al., 2009). SCRA were initially dissolved and sprayed onto inert vegetal material to be sold as “herbal incense”, “potpourri” or “legal high” labeled as “not for human consumption” under various marketing names (e.g., “Black Mamba”, “Ultimate Warrior”, “Mad Hatter”). SCRA were also commercialized directly in their powder form under their chemical designation (e.g., JWH-018, MAM-CHMINACA, UR-144).

Unlike natural cannabis products (e.g., floral cannabis, hashish, marijuana concentrates), SCRA are full agonists of the endocannabinoid CB1 and CB2 receptors inducing a stronger neuronal response (Brents and Prather, 2014, Huffman and Padgett, 2005). This enhanced neurological response is one of the main factors contributing to a large spectrum of observed adverse effects such as increased risk of psychosis (Every-Palmer, 2011; van Amsterdam, Brunt, & van den Brink, 2015), seizures and convulsions (Schneir, Cullen, & Ly, 2011), dependence (Zimmermann, et al., 2009), and kidney failure (Bhanushali, Jain, Fatima, Leisch, & Thornley-Brown, 2013; CDC, 2013a, CDC, 2013b; Kazory & Aiyer, 2013).

Despite legislative efforts to regulate new cannabinoids as soon as they reach the market (e.g., the U.S. government has scheduled various SCRA molecules five times in the last five years), banned SCRA are rapidly replaced by molecules presenting chemical variation(s) to bypass current legal interdictions (Cohen, 2014, Lindigkeit et al., 2009). For example, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has reported the emergence of 134 SCRA from the end of 2008 until end of 2014 (EMCDDA, 2015). Reported emergency department cases linked to SCRA have increased in the U.S. over the past three years (Riederer, et al., 2016). According to the American Association of Poison Control Centers (AAPCC), 7,779 calls for of synthetic cannabinoid exposures were reported in 2015 exceeding both annual cases reported in 2013 (2668) and 2014 (3682) (AAPCC, 2016).

Except for a small number of epidemiological surveys describing SCRA use (Barratt, Cakic, & Lenton, 2013; Castellanos, Singh, Thornton, Avila, & Moreno, 2011; Caviness, Tzilos, Anderson, & Stein, 2015; Hu, Primack, Barnett, & Cook, 2011; Johnson, Johnson, & Portier, 2013; Vandrey, Dunn, Fry, & Girling, 2012; Winstock and Barratt, 2013a, Winstock and Barratt, 2013b), most of this literature informs either the neuropharmacology and neurophysiology of these products (Grigoryev et al., 2011; Kavanagh, Grigoryev, Savchuk, Mikhura, & Formanovsky, 2013) or the adverse effects observed on emergency department patients (Besli, Ikiz, Yildirim, & Saltik, 2015; Bonar, Ashrafioun, & Ilgen, 2014; Johnson et al., 2013; Tait, Caldicott, Mountain, Hill, & Lenton, 2016). Collecting information regarding SCRA patterns of use and related effects remains challenging because SCRA users are sometimes difficult to reach through conventional epidemiological surveillance methods. Furthermore, not all SCRA users who have experienced negative effects require or seek medical attention, nor were those who did receive medical attention necessarily assessed for SCRA-related symptoms (Tait et al., 2016).

To overcome the challenges of identifying and recruiting SCRA users, we analyzed posts from web-forums dedicated to drug discussions. The last few years have seen an increased interest in the use of large-scale internet-based data as a source of information on evolving public health problems and emerging trends (Butler et al., 2007, Daniulaityte, Nahhas et al., 2015, Eysenbach, 2011, Lamy et al., 2016, Lazer et al., 2009, Miller and Sonderlund, 2010). Recent research has also demonstrated that social media analysis provides valuable information regarding new drug trends, such as the use of loperamide by opiate users to ease opiate withdrawal (Daniulaityte et al., 2013), or changes in attitudes and behaviors of a population of synthetic cannabinoid users in Norway (Bilgrei, 2016).

In contrast to other social media platforms (such as Twitter or Instagram), Web forums allow their users to post extensive comments about their drug use, share experiences or ask questions regarding new products and trends. These websites also favour dialogue between users, who can share their thoughts, advice, and techniques on similar topics. Analysis of such data can provide valuable information regarding effects, patterns of use, and opinions directly from the user’s perspective (Miller and Sønderlund, 2010, Schifano et al., 2006). Nevertheless, harnessing data on drug forums is a significant challenge due to the large amount of data displayed on Web forums. We used an advanced software platform, eDrugTrends (Daniulaityte, Nahhas et al., 2015, eDrugTrends, 2015), to collect and analyze forum posts related to SCRA and their effects, and conducted a longitudinal analysis of drug-focused web-forum posts. The key aims of this study are to: (1) identify the most common SCRA-related effects discussed on Web forums; and (2) analyze how frequencies of SCRA and their effects mentioned in Web forum discussions changed from January 2008 through September 2015.

Section snippets

Methods

The eDrugTrends system is a semi-automated comprehensive platform resulting from collaboration between social scientists in the Center for Interventions, Treatment and Addictions Research (CITAR) and computer scientists in the Ohio Center of Excellence in Knowledge-enabled Computing (Kno.e.sis Center) (eDrugTrends, 2015). This platform is designed to extract, process, and analyze social Web data, with the current application directed towards understanding cannabis and synthetic

Data extraction

The eDrugTrends platform collected a total of 19,823,726 drug-related posts (Bluelight: 1,558,832; Forum A: 18,170,129; Forum B: 94,765) written by 67,841 forums users. Forum users were identified by their unique ID serial for each forum. Counting users by their forum ID implies that (a) one individual could create several accounts in a web-forum and s/he will be considered as several different “forum users”; (b) the same individual will be identified as different users across several forums.

Discussion

To the best of our knowledge, this study is the first to evaluate the frequency and trends of effects associated with SCRA use based on web-forum data. Our analysis shows that the proportion of drug-related posts mentioning at least one SCRA and no other drug has consistently decreased since 2008 without completely disappearing. The most frequent categories of effects mentioned in SCRA-only posts are “High,” “Hallucinations,” “Anxiety,” “Euphoria,” “Nausea,” “Overdose,” and “Seizure.” These

Role of funding source

This study was supported by the National Institute on Drug Abuse (NIDA), Grant No. R01 DA039454-01 (Daniulaityte, PI; Sheth, PI). The funding source had no further role in the study design, in the collection, analysis and interpretation of the data, in the writing of the report, or in the decision to submit the paper for publication.

Monica Barratt is supported by a fellowship from the NHMRC (APP1070140). The National Drug and Alcohol Research Centre and the National Drug Research Institute are

Acknowledgements

This material is based in part on datasets obtained from Bluelight.org. Bluelight.org is a non-profit online community dedicated to reducing drug-related harm. This work was conducted with support from Bluelight.org. The content is solely the responsibility of the authors and does not necessarily represent the official views of Bluelight.org.
Conflict of interest statement

Monica Barratt is the Director of Research at Bluelight.org, a not-for-profit harm-reduction website.

References (104)

  • A. Grigoryev et al.

    Chromatography–mass spectrometry studies on the metabolism of synthetic cannabinoids JWH-018 and JWH-073, psychoactive components of smoking mixtures

    Journal of Chromatography B

    (2011)
  • C.R. Harris et al.

    Synthetic cannabinoid intoxication: A case series and review

    The Journal of Emergency Medicine

    (2013)
  • C.Y. Hopkins et al.

    A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids

    The Journal of Emergency Medicine

    (2013)
  • X. Hu et al.

    College students and use of K2: An emerging drug of abuse in young persons

    Substance Abuse Treatment, Prevention, and Policy

    (2011)
  • L.A. Johnson et al.

    Current legal highs

    The Journal of Emergency Medicine

    (2013)
  • L.M. Labay et al.

    Synthetic cannabinoid drug use as a cause or contributory cause of death

    Forensic Science International

    (2016)
  • F.R. Lamy et al.

    Those edibles hit hard: Exploration of Twitter data on cannabis edibles in the US

    Drug and Alcohol Dependence

    (2016)
  • R. Lindigkeit et al.

    Spice: A never ending story?

    Forensic Science International

    (2009)
  • M.L. Nolan et al.

    A public health approach to increased synthetic cannabinoid-related morbidity among New York City residents, 2014–2015

    International Journal of Drug Policy

    (2016)
  • F. Schifano et al.

    Drugs on the web; The Psychonaut 2002 EU project

    Progress in Neuro-Psychopharmacology & Biological Psychiatry

    (2006)
  • A.B. Schneir et al.

    Spice girls: Synthetic cannabinoid intoxication

    The Journal of Emergency Medicine

    (2011)
  • J.R. Simmons et al.

    Intoxication from smoking spice

    Annals of Emergency Medicine

    (2011)
  • R. Sutherland et al.

    New psychoactive substance use among regular psychostimulant users in Australia, 2010–2015

    Drug and Alcohol Dependence

    (2016)
  • N. Uchiyama et al.

    URB-754: A new class of designer drug and 12 synthetic cannabinoids detected in illegal products

    Forensic Science International

    (2013)
  • R. Vandrey et al.

    A survey study to characterize use of spice products (synthetic cannabinoids)

    Drug and Alcohol Dependence

    (2012)
  • AAPCC

    Synthetic cannabonoid data

    (2016)
  • V. Auwärter et al.

    ‘Spice’ and other herbal blends: Harmless incense or cannabinoid designer drugs?

    Journal of Mass Spectrometry

    (2009)
  • S. Banerji et al.

    Spice ain’t so nice

    Clinical Toxicology

    (2010)
  • M.J. Barratt et al.

    Patterns of synthetic cannabinoid use in Australia

    Drug and Alcohol Review

    (2013)
  • G.K. Bhanushali et al.

    AKI associated with synthetic cannabinoids: A case series

    Clinical Journal of the American Society of Nephrology

    (2013)
  • S. Bird et al.

    Natural language processing with python

    (2009)
  • M. Bozkurt et al.

    Clinical characteristics and laboratory test results of patients admitted to outpatient clinic for synthetic cannabinoid usage

    Dusunen Adam

    (2014)
  • L.K. Brents et al.

    The K2/spice phenomenon: Emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products

    Drug Metabolism Reviews

    (2014)
  • D.M. Bush et al.

    Update: Drug-related emergency department visits involving synthetic cannabinoids

    SAMHSA, Drug Abuse Warning Network

    (2014)
  • S.F. Butler et al.

    Internet surveillance: Content analysis and monitoring of product-specific internet prescription opioid abuse-related postings

    The Clinical Journal of Pain

    (2007)
  • C.M. Caviness et al.

    Synthetic cannabinoids: Use and predictors in a community sample of young adults

    Substance Abuse

    (2015)
  • Centers for Disease Control Prevention (CDC)

    Acute kidney injury associated with synthetic cannabinoid use-multiple states, 2013

    Morbidity and Mortality Weekly Report

    (2013)
  • Centers for Disease Control Prevention (CDC)

    Notes from the field: Severe illness associated with synthetic cannabinoid use-Brunswick, Georgia, 2013

    Morbidity and Mortality Weekly Report

    (2013)
  • J. Cohen et al.

    Clinical presentation of intoxication due to synthetic cannabinoids

    Pediatrics

    (2012)
  • J.A. Cohen

    Highs of tomorrow: Why new laws and policies are needed to meet the unique challenges of synthetic drugs

    The JL & Health

    (2014)
  • F.J. Damerau

    A technique for computer detection and correction of spelling errors

    Communications of the ACM

    (1964)
  • R. Daniulaityte et al.

    “Sub is a weird drug”: A web-based study of lay attitudes about use of buprenorphine to self-treat opioid withdrawal symptoms

    The American Journal on Addictions

    (2015)
  • A. Derungs et al.

    Symptoms, toxicities, and analytical results for a patient after smoking herbs containing the novel synthetic cannabinoid MAM-2201

    Forensic Toxicology

    (2013)
  • T. Devlin et al.

    Spline functions for logistic regression modeling

  • J. Doward

    Plague of cheap ‘spice’ strengthens its grip on homeless and jobless in northern towns

    (2015)
  • Drug Enforcement Administration

    Schedules of controlled substances: Temporary placement of five synthetic cannabinoids into schedule I

    (2016)
  • Drug Enforcement Administration. (2016). Special report: Synthetic cannabinoids and synthetic cathinones reported in...
  • eDrugTrends. Project Information. http://wiki.knoesis.org/index.php/EDrugTrends. (Retrieved 05 November...
  • EMCDDA

    New psychoactive substances in Europe

    An update from the EU early warning system (March 2015)

    (2015)
  • European Monitoring Centre for Drugs and Drug Addiction

    Perspectives on drugs: Synthetic cannabinoids in Europe

    (2013)
  • Cited by (32)

    • Listed for sale: Analyzing data on fentanyl, fentanyl analogs and other novel synthetic opioids on one cryptomarket

      2020, Drug and Alcohol Dependence
      Citation Excerpt :

      The Drug Abuse Ontology (DAO) was developed by the research team building on our prior work on web-based analytics for substance use epidemiology research (Cameron et al., 2013; Daniulaityte et al., 2015; Lamy et al., 2017). The DAO was created using Protégé software (Musen, 2015) and includes a comprehensive list of psychoactive substances based on available resources (e.g., Drug Enforcement Administration, National Institute on Drug Abuse, European Monitoring Centre for Drugs and Drug Addiction), prior research (e.g., Daniulaityte et al., 2015; Lamy et al., 2017), and preliminary examination of cryptomarket data. The DAO includes names of psychoactive substances (e.g., heroin, fentanyl, acetylfentanyl) including synthetic substances (e.g., U-48,800, MT-45), brand and generic denominations of pharmaceutical drugs (e.g., Fentora, Subutex) and slang terms (e.g., china white, oxy, fent).

    • A systematic review of natural language processing and text mining of symptoms from electronic patient-authored text data

      2019, International Journal of Medical Informatics
      Citation Excerpt :

      Years of publication ranged from 2003 to 2017 with over 95% (n = 20) of articles published in the last 10 years. The purposes of the 21 articles were diverse and focused on identification, detection, extraction, and/or description of symptom terms, including adverse drug events (n = 11) [16–26]; comparison of ePAT to another data source (n = 4), including a regulatory agency [27], molecular database [28], research study [29], or EHR [30]; content and/or sentiment analysis (n = 3) [31–33]; description of the patient experience (n = 2) [34,35]; and development of a classifier (n = 1) [36]. Table 2 organizes each study purpose as well as data source, text type, number of documents, and number of users chronologically to assess overall trends.

    View all citing articles on Scopus
    View full text